NovaBridge Reports Mature Phase 1b Givastomig Data at ESMO 2026
The company reported nearly 18 months of median follow-up, selection of an 8 mg/kg dose and FDA engagement, supporting registrational development in first-line metastatic gastroesophageal adenocarcinoma.
Story updates
11:04:03 AM UTC
SquawkNews
NovaBridge reported mature Phase 1b data for givastomig in first-line metastatic gastroesophageal adenocarcinoma, selected the 8 mg/kg dose, and said it has FDA alignment on a global registrational study protocol.Material DetailsContext by AI AnalystThis is a late-stage development update moving gi…